From the Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
Department of Pediatrics, Division of Pediatric Infectious Diseases.
Pediatr Infect Dis J. 2022 Nov 1;41(11):e481-e486. doi: 10.1097/INF.0000000000003680. Epub 2022 Aug 31.
Pediatric central nervous system (CNS) phaeohyphomycosis is a rare invasive fungal infection associated with high mortality.
We describe a child with progressive neurologic symptoms whose ultimate diagnosis was Cladophialophora bantiana -associated CNS phaeohyphomycosis. We discuss her clinical presentation, medical and surgical management and review the current literature.
A 9-year-old female presented with acute onset of headaches, ophthalmoplegia and ataxia. Initial infectious work-up was negative, including serial fungal cerebrospinal fluid cultures. Over 2 months, she experienced progressive cognitive and motor declines, and imaging revealed worsening meningitis, ventriculitis and cerebritis. Ultimately, Cladophialophora was detected by plasma metagenomic next-generation sequencing (mNGS). Fourth ventricle fluid sampling confirmed the diagnosis of C. bantiana infection. Given the extent of her disease, complete surgical resection was not feasible. She required multiple surgical debridement procedures and prolonged antifungal therapy, including the instillation of intraventricular amphotericin B. With aggressive surgical and medical management, despite her continued neurologic deficits, she remains alive 3 years after her initial diagnosis. To our knowledge, this is one of a few published pediatric cases of CNS phaeohyphomycosis and the first with the causative pathogen identified by plasma mNGS.
CNS phaeohyphomycosis is a serious, life-threatening infection. The preferred management includes a combination of surgical resection and antifungal therapy. In cases complicated by refractory ventriculitis, intraventricular antifungal therapy can be considered as adjuvant therapy. Direct sampling of the CNS for pathogen identification and susceptibility testing is the gold standard for diagnosis; however, the use of plasma mNGS may expedite the diagnosis.
小儿中枢神经系统(CNS)暗色丝孢霉病是一种罕见的侵袭性真菌感染,死亡率高。
我们描述了一名患有进行性神经系统症状的儿童,最终诊断为棒曲霉相关 CNS 暗色丝孢霉病。我们讨论了她的临床表现、医疗和手术管理,并回顾了当前的文献。
一名 9 岁女性出现急性头痛、眼肌麻痹和共济失调。最初的感染性检查呈阴性,包括连续的真菌性脑脊液培养。在 2 个月的时间里,她经历了认知和运动功能的逐渐下降,影像学显示脑膜炎、脑室炎和脑质炎加重。最终,通过血浆宏基因组下一代测序(mNGS)检测到棒曲霉。第四脑室液采样证实了 C. bantiana 感染的诊断。鉴于她的疾病范围,完全手术切除不可行。她需要多次手术清创和长期抗真菌治疗,包括脑室注射两性霉素 B。通过积极的手术和医疗管理,尽管她仍有持续的神经功能缺损,但在最初诊断后的 3 年内仍存活。据我们所知,这是少数几例已发表的小儿 CNS 暗色丝孢霉病病例之一,也是首例通过血浆 mNGS 确定病原体的病例。
CNS 暗色丝孢霉病是一种严重的、危及生命的感染。首选的治疗方法包括手术切除和抗真菌治疗相结合。在并发难治性脑室炎的情况下,可以考虑脑室内抗真菌治疗作为辅助治疗。直接从 CNS 取样进行病原体鉴定和药敏试验是诊断的金标准;然而,使用血浆 mNGS 可能会加速诊断。